Brief: Immunovant Reports Financial Results For The Quarter Ended June 30, 2022
05/08/2022 13:00
Aug 5 (Reuters) - Immunovant Inc IMVT.O :
* IMMUNOVANT REPORTS FINANCIAL RESULTS AND RECENT BUSINESS
UPDATES
FOR THE QUARTER ENDED JUNE 30, 2022
* QUARTERLY LOSS PER SHARE $0.35
* EXPECTS TO CONTINUE TO INCUR FLUCTUATING QUARTERLY
OPERATING
CASH FLOWS IN FUTURE
* CASH BALANCE OF $427 MILLION AS OF JUNE 30, 2022 IS
EXPECTED TO
PROVIDE CASH RUNWAY INTO CALENDAR YEAR 2025
Source text for Eikon: ID:nGNX5D3jSq
Further company coverage: IMVT.O
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million